Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2012

Open Access 01-12-2012 | Research

Molecular markers associated with outcome and metastasis in human pancreatic cancer

Authors: Anke Van den Broeck, Hugo Vankelecom, Rudy Van Eijsden, Olivier Govaere, Baki Topal

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2012

Login to get access

Abstract

Background

Pancreatic ductal adenocarcinoma (PDAC) is a heterogeneous cancer in which differences in survival rates might be related to a variety in gene expression profiles. Although the molecular biology of PDAC begins to be revealed, genes or pathways that specifically drive tumour progression or metastasis are not well understood.

Methods

We performed microarray analyses on whole-tumour samples of 2 human PDAC subpopulations with similar clinicopathological features, but extremely distinct survival rates after potentially curative surgery, i.e. good outcome (OS and DFS > 50 months, n = 7) versus bad outcome (OS < 19 months and DFS < 7 months, n = 10). Additionally, liver- and peritoneal metastases were analysed and compared to primary cancer tissue (n = 11).

Results

The integrin and ephrin receptor families were upregulated in all PDAC samples, irrespective of outcome, supporting an important role of the interaction between pancreatic cancer cells and the surrounding desmoplastic reaction in tumorigenesis and cancer progression. Moreover, some components such as ITGB1 and EPHA2 were upregulated in PDAC samples with a poor outcome, Additionally, overexpression of the non-canonical Wnt/β-catenin pathway and EMT genes in PDAC samples with bad versus good outcome suggests their contribution to the invasiveness of pancreatic cancer, with β-catenin being also highly upregulated in metastatic tissue.

Conclusions

Components of the integrin and ephrin pathways and EMT related genes, might serve as molecular markers in pancreatic cancer as their expression seems to be related with prognosis.
Appendix
Available only for authorised users
Literature
1.
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62 (1): 10-29. 10.3322/caac.20138.CrossRefPubMed
2.
Van den Broeck A, Sergeant G, Ectors N, Van Steenbergen W, Aerts R, Topal B: Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol. 2009, 35 (6): 600-604. 10.1016/j.ejso.2008.12.006.CrossRefPubMed
3.
Neoptolemos JP: Adjuvant treatment of pancreatic cancer. Eur J Cancer. 2011, 47 (Suppl 3): S378-S380.CrossRefPubMed
4.
Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW: Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004, 91 (5): 586-594. 10.1002/bjs.4484.CrossRefPubMed
5.
Ozaki H, Hiraoka T, Mizumoto R, Matsuno S, Matsumoto Y, Nakayama T, Tsunoda T, Suzuki T, Monden M, Saitoh Y, Yamauchi H, Ogata Y: The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection. Surg Today. 1999, 29 (1): 16-22. 10.1007/BF02482964.CrossRefPubMed
6.
Iacobuzio-Donahue CA, Ashfaq R, Maitra A, Adsay NV, Shen-Ong GL, Berg K, Hollingsworth MA, Cameron JL, Yeo CJ, Kern SE, Goggins M, Hruban RH: Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res. 2003, 63 (24): 8614-8622.PubMed
7.
Grutzmann R, Boriss H, Ammerpohl O, Luttges J, Kalthoff H, Schackert HK, Kloppel G, Saeger HD, Pilarsky C: Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes. Oncogene. 2005, 24 (32): 5079-5088. 10.1038/sj.onc.1208696.CrossRefPubMed
8.
Kim HN, Choi DW, Lee KT, Lee JK, Heo JS, Choi SH, Paik SW, Rhee JC, Lowe AW: Gene expression profiling in lymph node-positive and lymph node-negative pancreatic cancer. Pancreas. 2007, 34 (3): 325-334. 10.1097/MPA.0b013e3180317b01.CrossRefPubMed
9.
Campagna D, Cope L, Lakkur SS, Henderson C, Laheru D, Iacobuzio-Donahue CA: Gene expression profiles associated with advanced pancreatic cancer. Int J Clin Exp Pathol. 2008, 1 (1): 32-43.PubMedCentralPubMed
10.
Hirono S, Yamaue H, Hoshikawa Y, Ina S, Tani M, Kawai M, Ushijima M, Matsuura M, Saiki Y, Saiura A, Yamamoto J, Miki Y, Noda T: Molecular markers associated with lymph node metastasis in pancreatic ductal adenocarcinoma by genome-wide expression profiling. Cancer Sci. 2010, 101 (1): 259-266. 10.1111/j.1349-7006.2009.01359.x.CrossRefPubMed
11.
Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW: Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011, 17 (4): 500-503. 10.1038/nm.2344.PubMedCentralCrossRefPubMed
12.
Kleeff J, Beckhove P, Esposito I, Herzig S, Huber PE, Lohr JM, Friess H: Pancreatic cancer microenvironment. Int J Cancer. 2007, 121 (4): 699-705. 10.1002/ijc.22871.CrossRefPubMed
13.
Farrow B, Albo D, Berger DH: The role of the tumor microenvironment in the progression of pancreatic cancer. J Surg Res. 2008, 149 (2): 319-328. 10.1016/j.jss.2007.12.757.CrossRefPubMed
14.
Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003, 4 (2): 249-264. 10.1093/biostatistics/4.2.249.CrossRefPubMed
15.
Bolstad BM, Irizarry RA, Astrand M, Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003, 19 (2): 185-193. 10.1093/bioinformatics/19.2.185.CrossRefPubMed
16.
Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004, 3 (1): 1554-6115.
17.
Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, Collins PJ, de Longueville F, Kawasaki ES, Lee KY, Luo Y, Sun YA, Willey JC, Setterquist RA, Fischer GM, Tong W, Dragan YP, Dix DJ, Frueh FW, Goodsaid FM, Herman D, Jensen RV, Johnson CD, Lobenhofer EK, Puri RK, Schrf U, Thierry-Mieg J, Wang C, Wilson M, Wolber PK, etal: The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol. 2006, 24 (9): 1151-1161. 10.1038/nbt1239.CrossRefPubMed
18.
Carmona-Saez P, Chagoyen M, Tirado F, Carazo JM, Pascual-Montano A: GENECODIS: a web-based tool for finding significant concurrent annotations in gene lists. Genome Biol. 2007, 8 (1): R3-10.1186/gb-2007-8-1-r3.PubMedCentralCrossRefPubMed
19.
Nakamura T, Furukawa Y, Nakagawa H, Tsunoda T, Ohigashi H, Murata K, Ishikawa O, Ohgaki K, Kashimura N, Miyamoto M, Hirano S, Kondo S, Katoh H, Nakamura Y, Katagiri T: Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. Oncogene. 2004, 23 (13): 2385-2400. 10.1038/sj.onc.1207392.CrossRefPubMed
20.
Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, Loader J, Terris B, Stamp G, Baron A, Scarpa A, Lemoine NR: Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene. 2002, 21 (29): 4587-4594. 10.1038/sj.onc.1205570.CrossRefPubMed
21.
Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, etal: Inhibition of Hedgehog signalling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009, 324 (5933): 1457-1461. 10.1126/science.1171362.PubMedCentralCrossRefPubMed
22.
Mueller MT, Hermann PC, Witthauer J, Rubio-Viqueira B, Leicht SF, Huber S, Ellwart JW, Mustafa M, Bartenstein P, D'Haese JG, Schoenberg MH, Berger F, Jauch KW, Hidalgo M, Heeschen C: Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology. 2009, 137 (3): 1102-1113. 10.1053/j.gastro.2009.05.053.CrossRefPubMed
23.
Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M: J Clin Oncol. 2011, 29 (34): 4548-4554. 10.1200/JCO.2011.36.5742.PubMedCentralCrossRefPubMed
24.
Desgrosellier JS, Cheresh DA: Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010, 10 (1): 9-22. 10.1038/nrc2748.PubMedCentralCrossRefPubMed
25.
Grzesiak JJ, Ho JC, Moossa AR, Bouvet M: The integrin-extracellular matrix axis in pancreatic cancer. Pancreas. 2007, 35 (4): 293-301. 10.1097/mpa.0b013e31811f4526.CrossRefPubMed
26.
Hazlehurst LA, Landowski TH, Dalton WS: Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene. 2003, 22 (47): 7396-7402. 10.1038/sj.onc.1206943.CrossRefPubMed
27.
Arao S, Masumoto A, Otsuki M: Beta1 integrins play an essential role in adhesion and invasion of pancreatic carcinoma cells. Pancreas. 2000, 20 (2): 129-137. 10.1097/00006676-200003000-00004.CrossRefPubMed
28.
Grzesiak JJ, Tran Cao HS, Burton DW, Kaushal S, Vargas F, Clopton P, Snyder CS, Deftos LJ, Hoffman RM, Bouvet M: Knockdown of the beta(1) integrin subunit reduces primary tumor growth and inhibits pancreatic cancer metastasis. Int J Cancer. 2011, 129 (12): 2905-2915. 10.1002/ijc.25942.PubMedCentralCrossRefPubMed
29.
30.
Ansuini H, Meola A, Gunes Z, Paradisi V, Pezzanera M, Acali S, Santini C, Luzzago A, Mori F, Lazzaro D, Ciliberto G, Nicosia A, La Monica N, Vitelli A: Anti-EphA2 Antibodies with Distinct In Vitro Properties Have Equal In Vivo Efficacy in Pancreatic Cancer. J Oncol. 2009, 2009: 951917-PubMedCentralCrossRefPubMed
31.
Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE: EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene. 2004, 23 (7): 1448-1456. 10.1038/sj.onc.1207247.CrossRefPubMed
32.
Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA: Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006, 20 (10): 1218-1249. 10.1101/gad.1415606.CrossRefPubMed
33.
Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernandez-del Castillo C, Yajnik V, Antoniu B, McMahon M, Warshaw AL: Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 2003, 425 (6960): 851-856. 10.1038/nature02009.PubMedCentralCrossRefPubMed
34.
Morris JP, Wang SC, Hebrok M: KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer. 2010, 10 (10): 683-695. 10.1038/nrc2899.PubMedCentralCrossRefPubMed
35.
Pilarsky C, Ammerpohl O, Sipos B, Dahl E, Hartmann A, Wellmann A, Braunschweig T, Lohr M, Jesenofsky R, Friess H, Wente MN, Kristiansen G, Jahnke B, Denz A, Rückert F, Schackert HK, Klöppel G, Kalthoff H, Saeger HD, Grützmann R: Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling. J Cell Mol Med. 2008, 12 (6B): 2823-2835. 10.1111/j.1582-4934.2008.00289.x.PubMedCentralCrossRefPubMed
36.
Katoh M: Transcriptional mechanisms of WNT5A based on NF-kappaB, Hedgehog, TGFbeta, and Notch signalling cascades. Int J Mol Med. 2009, 23 (6): 763-769.CrossRefPubMed
37.
Takahashi N, Fukushima T, Yorita K, Tanaka H, Chijiiwa K, Kataoka H: Dickkopf-1 is overexpressed in human pancreatic ductal adenocarcinoma cells and is involved in invasive growth. Int J Cancer. 2010, 126 (7): 1611-1620.PubMed
38.
Wang Z, Ahmad A, Li Y, Azmi AS, Miele L, Sarkar FH: Targeting notch to eradicate pancreatic cancer stem cells for cancer therapy. Anticancer Res. 2011, 31 (4): 1105-1113.PubMed
39.
Wang YH, Li F, Luo B, Wang XH, Sun HC, Liu S, Cui YQ, Xu XX: A side population of cells from a human pancreatic carcinoma cell line harbors cancer stem cell characteristics. Neoplasma. 2009, 56 (5): 371-378. 10.4149/neo_2009_05_371.CrossRefPubMed
40.
Sarkar FH, Li Y, Wang Z, Kong D: Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chir. 2009, 64 (5): 489-500.PubMedCentralPubMed
41.
Song Y, Washington MK, Crawford HC: Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res. 2010, 70 (5): 2115-2125. 10.1158/0008-5472.CAN-09-2979.PubMedCentralCrossRefPubMed
42.
Tano K, Mizuno R, Okada T, Rakwal R, Shibato J, Masuo Y, Ijiri K, Akimitsu N: MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes. FEBS Lett. 2010, 584 (22): 4575-4580. 10.1016/j.febslet.2010.10.008.CrossRefPubMed
43.
Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY, Zhang F, Wu LM, Chen LM, Zheng SS: Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol. 2011, in press
44.
Niedergethmann M, Alves F, Neff JK, Heidrich B, Aramin N, Li L, Pilarsky C, Grutzmann R, Allgayer H, Post S, Gretz N: Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model. Br J Cancer. 2007, 97 (10): 1432-1440. 10.1038/sj.bjc.6604031.PubMedCentralCrossRefPubMed
45.
Nomura H, Nishimori H, Yasoshima T, Hata F, Tanaka H, Nakajima F, Honma T, Araya J, Kamiguchi K, Isomura H, Sato N, Denno R, Hirata K: A new liver metastatic and peritoneal dissemination model established from the same human pancreatic cancer cell line: analysis using cDNA macroarray. Clin Exp Metastasis. 2002, 19 (5): 391-399. 10.1023/A:1016370532618.CrossRefPubMed
46.
Suemizu H, Monnai M, Ohnishi Y, Ito M, Tamaoki N, Nakamura M: Identification of a key molecular regulator of liver metastasis in human pancreatic carcinoma using a novel quantitative model of metastasis in NOD/SCID/gammacnull (NOG) mice. Int J Oncol. 2007, 31 (4): 741-751.PubMed
47.
Shi WD, Meng ZQ, Chen Z, Lin JH, Zhou ZH, Liu LM: Identification of liver metastasis-related genes in a novel human pancreatic carcinoma cell model by microarray analysis. Cancer Lett. 2009, 283 (1): 84-91. 10.1016/j.canlet.2009.03.030.CrossRefPubMed
48.
Fu Y, Zheng S, An N, Athanasopoulos T, Popplewell L, Liang A, Li K, Hu C, Zhu Y: Beta-catenin as a potential key target for tumor suppression. Int J Cancer. 2011, 129 (7): 1541-1551. 10.1002/ijc.26102.CrossRefPubMed
49.
Orlichenko LS, Radisky DC: Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development. Clin Exp Metastasis. 2008, 25 (6): 593-600. 10.1007/s10585-008-9143-9.CrossRefPubMed
50.
51.
Decarlo K, Emley A, Dadzie OE, Mahalingam M: Laser capture microdissection: methods and applications. Methods Mol Biol. 2011, 755: 1-15. 10.1007/978-1-61779-163-5_1.CrossRefPubMed
Metadata
Title
Molecular markers associated with outcome and metastasis in human pancreatic cancer
Authors
Anke Van den Broeck
Hugo Vankelecom
Rudy Van Eijsden
Olivier Govaere
Baki Topal
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2012
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-31-68

Other articles of this Issue 1/2012

Journal of Experimental & Clinical Cancer Research 1/2012 Go to the issue

Research

The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells

Research

Are there candidates for high-dose chemotherapy in ovarian carcinoma?

Research

Ku80 is highly expressed in lung adenocarcinoma and promotes cisplatin resistance

Research

Oncolytic adenovirus armed with IL-24 Inhibits the growth of breast cancer in vitro and in vivo

Research

Lysosomal Membrane Permeabilization is an Early Event in Sigma-2 Receptor Ligand Mediated Cell Death in Pancreatic Cancer

Research

Response gene to complement-32 enhances metastatic phenotype by mediating transforming growth factor beta-induced epithelial-mesenchymal transition in human pancreatic cancer cell line BxPC-3
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits